Ceribell Tops Q2 Revenue, Lifts Full-Year Outlook, and Locks In $60M Credit Facility

summarizeSummary

Ceribell posted Q2 2026 revenue of $28.1M, beating estimates, and raised full-year guidance to $114M-$117M. The company also secured a new $60M credit facility and announced multiple FDA clearances.

check_boxKey Events · Earnings and Guidance · CBLL

• Q2 Revenue Beat and Raised Guidance

  Revenue of $28.1M grew 33% YoY, exceeding the $27.3M consensus. Full-year 2026 guidance raised to $114M-$117M, representing 28-31% growth.

• New $60M Credit Facility

  Secured a new credit facility with $30M term loan and $30M revolver, plus $25M uncommitted accordion, refinancing existing debt and adding liquidity.

• Gross Margin Expansion

  Gross margin reached 92%, up from 88% a year ago, benefiting from manufacturing cost reductions and a one-time tariff refund.

• FDA Clearances and Product Pipeline

  Received 510(k) clearances for Epileptiform Abnormality Detection and Artifact Reduction algorithms, and new recorder/headband designs for next-gen hardware.

auto_awesomeAnalysis · CBLL · Industrial Applications And Services

A standout second quarter saw revenue climb 33% year-over-year to $28.1 million, comfortably clearing the $27.3 million consensus. Bolstered by that momentum, full-year 2026 guidance was raised to $114–$117 million, implying 28–31% growth, while a new $60 million credit facility further fortifies the balance sheet. Gross margins expanded to 92%, aided by a one-time tariff refund, even as operating expenses rose 37% on commercial investments and IP litigation costs. The net loss widened to $19.3 million, but adjusted EBITDA loss narrowed slightly to $9.8 million. With $129.3 million in cash and equivalents and multiple FDA clearances for next-generation hardware and algorithms, the company is well-positioned to sustain its growth trajectory.